Jane.Moate

Professor Surinder Birring to present IPF COMFORT phase 2 study data at the 10th American Cough Conference. Professor Surinder Birring, Consultant Respiratory Physician and Professor of Respiratory Medicine at King’s…

Dr Steve Pawsey, CMO at NeRRe Therapeutics to present at the 9th American Cough Conference Dr Steve Pawsey, Chief Medical Officer at NeRRe Therapeutics to present at the 9th American…

NeRRe Therapeutics raises £20 million in a Series B2 financing round New funds to evaluate orvepitant as a treatment for the disabling chronic cough associated with idiopathic pulmonary fibrosis (IPF).…

Dr Steve Pawsey, Chief Medical Officer at NeRRe Therapeutics to Present at The Eleventh International Cough Symposium Virtual Event, 21 - 22 January 2021, London, UK Steve will be presenting…

Dr Mary Kerr, CEO of NeRRe Therapeutics to present at Biotech Showcase virtual event 11-15 January 2021. The Biotech digital showcase event is being delivered digitally in 2021 and showcases…

Dr Mary Kerr, CEO of NeRRe Therapeutics to present at Biotech Showcase in San Francisco on 13 January 2020, at 2.30PM, Franciscan C (Ballroom Level)

European Respiratory Society International Congress, Madrid 29 September 2019 Dr Steve Pawsey, CMO at NeRRe Therapeutics presents a poster at the European Respiratory Society, Madrid 29 September 2019 entitled :…

NeRRe Therapeutics Announces Publication of Positive Results in a Phase 2 Pilot Study of Orvepitant in Chronic Refractory Cough NeRRe Therapeutics is pleased to report that the positive Phase 2…

~ Statistically significant and clinically relevant improvements in patient reported outcomes in refractory chronic cough ~ Findings support further development of orvepitant in refractory chronic cough and meetings with the…

8th January 2019: NeRRe Therapeutics CEO, Dr Mary Kerr, presents at the Biotech Showcase, 10:30 Franciscan – D (Ballroom Level), Hilton San Francisco, San Francisco, CA 94102, USA